Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study.
hepatocellular carcinoma
nonalcoholic fatty liver disease
sorafenib
survival
toxicity
Journal
Therapeutic advances in gastroenterology
ISSN: 1756-283X
Titre abrégé: Therap Adv Gastroenterol
Pays: England
ID NLM: 101478893
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
12
2021
accepted:
21
04
2022
entrez:
6
10
2022
pubmed:
7
10
2022
medline:
7
10
2022
Statut:
epublish
Résumé
The impact of nonalcoholic fatty liver disease (NAFLD) on overall survival (OS), treatment response and toxicity in patients with hepatocellular carcinoma (HCC) treated with sorafenib is unknown. We examined the impact of NAFLD on survival and toxicity in an international cohort of patients receiving sorafenib. Clinical and demographic data were collected from patients consecutively treated at specialist centres in Europe and North America. The impact of NAFLD on OS, sorafenib-specific survival and toxicity compared with other aetiologies of liver disease using multivariable Cox-proportional hazards and logistic regression modelling was assessed. A total of 5201 patients received sorafenib; 183 (3.6%) had NAFLD-associated HCC. NAFLD-associated HCC patients were more likely to be older women (median age 65.8 Survival in HCC does not appear to be influenced by the presence of NAFLD. NAFLD-associated HCC derive similar clinical benefit from sorafenib compared with other aetiologies.
Sections du résumé
Background
UNASSIGNED
The impact of nonalcoholic fatty liver disease (NAFLD) on overall survival (OS), treatment response and toxicity in patients with hepatocellular carcinoma (HCC) treated with sorafenib is unknown. We examined the impact of NAFLD on survival and toxicity in an international cohort of patients receiving sorafenib.
Methods
UNASSIGNED
Clinical and demographic data were collected from patients consecutively treated at specialist centres in Europe and North America. The impact of NAFLD on OS, sorafenib-specific survival and toxicity compared with other aetiologies of liver disease using multivariable Cox-proportional hazards and logistic regression modelling was assessed.
Results
UNASSIGNED
A total of 5201 patients received sorafenib; 183 (3.6%) had NAFLD-associated HCC. NAFLD-associated HCC patients were more likely to be older women (median age 65.8
Conclusion
UNASSIGNED
Survival in HCC does not appear to be influenced by the presence of NAFLD. NAFLD-associated HCC derive similar clinical benefit from sorafenib compared with other aetiologies.
Identifiants
pubmed: 36199289
doi: 10.1177/17562848221100106
pii: 10.1177_17562848221100106
pmc: PMC9527996
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17562848221100106Informations de copyright
© The Author(s), 2022.
Déclaration de conflit d'intérêts
Competing Interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RS received lecture fees from Bayer Healthcare; consulting fees from EISAI, Roche, FALK Foundation; and research funding (to institution) from Incyte, Boston Scientific, AAA and Astex pharmaceuticals. MS received lecture fees from SIRTEX Medical, Cook, Boston Scientific, Falk Foundation, Siemens Healthcare; research funding (to institution) from Bayer and SIRTEX medical. DB: advisory for Bayer HealthCare and Boston Scientific, lecture fees from Falk Foundation. VCT – Honoraria/Advisory Boards: BMS, Eisai, Ipsen, Roche; Research Funding (To Institution): Bayer, Eisai, Ipsen. JS received the Australia Fellowship (Gilead Sciences) in 2017 and 2019.
Références
Hepatology. 2015 Dec;62(6):1723-30
pubmed: 26274335
Eur J Cancer. 2018 Dec;105:1-9
pubmed: 30384012
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
J Hepatol. 2017 Aug;67(2):302-309
pubmed: 28336466
Clin Gastroenterol Hepatol. 2015 Mar;13(3):594-601.e1
pubmed: 25148760
J Hepatol. 2012 Oct;57(4):821-9
pubmed: 22727733
J Clin Oncol. 2017 Nov 1;35(31):3575-3581
pubmed: 28872925
Hepatology. 2016 Mar;63(3):827-38
pubmed: 26599351
Gastroenterology. 2021 Jan;160(1):331-345.e6
pubmed: 33010248
J Hepatol. 2010 Aug;53(2):372-84
pubmed: 20494470
Curr Hypertens Rep. 2018 Feb 26;20(2):12
pubmed: 29480368
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
World J Gastroenterol. 2015 Jan 28;21(4):1189-96
pubmed: 25632192
J Hepatol. 2019 Dec;71(6):1175-1183
pubmed: 31449860
Lancet. 2014 Aug 30;384(9945):755-65
pubmed: 25129328
J Clin Oncol. 2017 Feb 20;35(6):622-628
pubmed: 28045619
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428
pubmed: 31028350
Gastroenterology. 2018 Dec;155(6):1828-1837.e2
pubmed: 30144434
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
Eur J Cancer. 2012 Sep;48(14):2137-45
pubmed: 22446023
Hepatology. 2014 Jun;59(6):2188-95
pubmed: 24375711
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
J Gastroenterol. 2011 Oct;46(10):1230-7
pubmed: 21748549
Aliment Pharmacol Ther. 2017 Dec;46(11-12):1061-1069
pubmed: 28960360
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
Lancet Gastroenterol Hepatol. 2016 Oct;1(2):156-164
pubmed: 28404072
Clin Gastroenterol Hepatol. 2012 Dec;10(12):1342-1359.e2
pubmed: 23041539
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Br J Cancer. 2021 Apr;124(8):1388-1397
pubmed: 33531690
J Gastroenterol. 2009;44 Suppl 19:89-95
pubmed: 19148800
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Liver Cancer. 2019 Jul;8(4):281-294
pubmed: 31602371
J Hepatol. 2018 Oct;69(4):896-904
pubmed: 29886156
J Hepatol. 2016 Aug;65(2):425-43
pubmed: 27091791
Liver Cancer. 2019 Nov;8(6):491-504
pubmed: 31799206
Nature. 2016 Mar 10;531(7593):253-7
pubmed: 26934227
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Hepatol. 2014 Jan;60(1):110-7
pubmed: 23978719
Gastroenterology. 2002 Jul;123(1):134-40
pubmed: 12105842
Diabetes Metab Res Rev. 2012 Feb;28(2):109-22
pubmed: 21898753
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184
pubmed: 30647010
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85
pubmed: 21623852
J Hepatol. 2015 Jul;63(1):237-64
pubmed: 25911335
Endocr Pract. 2015 Apr;21(4):438-47
pubmed: 25877012
Lancet. 2011 Aug 27;378(9793):804-14
pubmed: 21872749
Am J Gastroenterol. 2012 Feb;107(2):253-61
pubmed: 22008893
Hepatology. 2014 Nov;60(5):1767-75
pubmed: 24839253
J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):365-367
pubmed: 28587579
Am J Gastroenterol. 2016 Nov;111(11):1573-1580
pubmed: 27527741